Company intelligence / Profile preview
Suzhou Zelgen Biopharmaceuticals
Kunshan, Jiangsu, Chinazelgen.com ↗
- Ownership
- Private
- Employees
- ~910
- Development stage
- Other
01
Overview
Suzhou Zelgen Biopharmaceuticals has several approved drugs (donafenib, recombinant human thrombin) and late-stage assets (jacktinib tablets, recombinant human thyroid-stimulating hormone for injection) with multiple programs in NDA/Phase 3, and early-stage biologics and immuno-oncology assets under Phase 1/2 clinical trials. The company obtained its first drug approval in China in 2021 (donafenib) and continues to expand its presence, particularly in oncology and immunology. Ongoing trials are exploring further indications and combination approaches, especially for liver cancer and myeloproliferative neoplasms.
- Therapeutic areas
- OncologyHematologyImmunologyGastroenterology
- Modalities
- Small moleculeMonoclonal antibodyBispecific monoclonal antibodyRecombinant protein
- Industry
- Biotech
02
Drug pipeline
18 assets17 more assets in the full pipeline.
Request access →03
Partnerships
International research institutions (undisclosed)Academic collaborations (details below)
Beyond the preview
Go deeper on Suzhou Zelgen Biopharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Suzhou Zelgen Biopharmaceuticals.